NASDAQ:CRSP CRISPR Therapeutics - CRSP Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding CRISPR Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. $56.01 -0.11 (-0.20%) (As of 02/3/2023 11:47 AM ET) Add Compare Share Share Today's Range$53.38▼$56.1150-Day Range$39.19▼$56.1252-Week Range$38.94▼$86.95Volume488,796 shsAverage Volume1.07 million shsMarket Capitalization$4.39 billionP/E RatioN/ADividend YieldN/APrice Target$98.22 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media CRISPR Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.53 Rating ScoreUpside/Downside80.7% Upside$98.22 Price TargetShort InterestHealthy13.16% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.23Based on 9 Articles This WeekInsider TradingSelling Shares$3.66 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($9.25) to ($8.21) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.04 out of 5 starsMedical Sector515th out of 1,029 stocksBiological Products, Except Diagnostic Industry82nd out of 169 stocks 3.3 Analyst's Opinion Consensus RatingCRISPR Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.53, and is based on 10 buy ratings, 6 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $98.22, CRISPR Therapeutics has a forecasted upside of 80.7% from its current price of $54.36.Amount of Analyst CoverageCRISPR Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted13.16% of the float of CRISPR Therapeutics has been sold short.Short Interest Ratio / Days to CoverCRISPR Therapeutics has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in CRISPR Therapeutics has recently decreased by 5.73%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCRISPR Therapeutics does not currently pay a dividend.Dividend GrowthCRISPR Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CRSP. Previous Next 1.8 News and Social Media Coverage News SentimentCRISPR Therapeutics has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for CRISPR Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 43 people have searched for CRSP on MarketBeat in the last 30 days. This is a decrease of -7% compared to the previous 30 days.MarketBeat FollowsOnly 23 people have added CRISPR Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -15% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CRISPR Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,660,750.00 in company stock.Percentage Held by InsidersOnly 5.30% of the stock of CRISPR Therapeutics is held by insiders.Percentage Held by Institutions71.51% of the stock of CRISPR Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CRISPR Therapeutics are expected to grow in the coming year, from ($9.25) to ($8.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CRISPR Therapeutics is -6.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CRISPR Therapeutics is -6.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCRISPR Therapeutics has a P/B Ratio of 1.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About CRISPR Therapeutics (NASDAQ:CRSP) StockCRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Read More Receive CRSP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CRSP Stock News HeadlinesFebruary 2, 2023 | msn.com3 CRISPR Stocks to Buy Now Or You’ll Be Kicking Yourself LaterFebruary 1, 2023 | msn.comJim Cramer Says This Is 'One Of Those Crazy Science Stocks That In This Market Will Work Perfectly'February 3, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! February 1, 2023 | americanbankingnews.comCRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni Sells 25,000 Shares of StockJanuary 31, 2023 | americanbankingnews.comCRISPR Therapeutics AG (NASDAQ:CRSP) Short Interest UpdateJanuary 31, 2023 | americanbankingnews.comCRISPR Therapeutics AG (NASDAQ:CRSP) Receives $98.22 Consensus Price Target from AnalystsJanuary 26, 2023 | americanbankingnews.comBrokers Set Expectations for CRISPR Therapeutics AG's Q1 2023 Earnings (NASDAQ:CRSP)January 20, 2023 | finance.yahoo.comA Look At The Fair Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)February 3, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! January 18, 2023 | markets.businessinsider.com3 CRISPR Stocks That Will Make You Filthy Rich in 10 YearsJanuary 13, 2023 | seekingalpha.comPrime Medicine 'Crispr 3.0' Vs. Crispr TherapeuticsJanuary 4, 2023 | finance.yahoo.comCathie Wood Is Buying These Top Growth Stocks -- and Both Could Make You Rich Over TimeDecember 20, 2022 | finanznachrichten.deCRISPR Therapeutics AG: CRISPR Therapeutics Announces the Appointment of Alex Harding, M.D., M.B.A., as Head of Business DevelopmentDecember 17, 2022 | finance.yahoo.com3 Beaten-Down Stocks That Could Explode Higher in 2023December 13, 2022 | markets.businessinsider.comNeedham Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)November 12, 2022 | finance.yahoo.comWe Think CRISPR Therapeutics (NASDAQ:CRSP) Can Afford To Drive Business GrowthNovember 10, 2022 | finance.yahoo.comCRISPR Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual MeetingNovember 9, 2022 | finance.yahoo.com3 Healthcare Stocks That Could Go ParabolicNovember 7, 2022 | finance.yahoo.comWhy Shares of CRISPR Therapeutics Dropped 19.9% in OctoberNovember 2, 2022 | apnews.comCRISPR Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial ResultsNovember 2, 2022 | msn.comExpert Ratings for CRISPR TherapeuticsNovember 2, 2022 | markets.businessinsider.comWhat 8 Analyst Ratings Have To Say About CRISPR TherapeuticsNovember 2, 2022 | finance.yahoo.comCRISPR Therapeutics (CRSP) Q3 Earnings Top, Sales Lag EstimatesOctober 29, 2022 | finance.yahoo.comWhy Shares of Vertex Pharmaceuticals Jumped 9.03% on FridayOctober 27, 2022 | marketwatch.comCRISPR Therapeutics Chief Operating Officer Lawrence Klein Resigns >CRSPOctober 27, 2022 | finance.yahoo.comEarnings Preview: Exact Sciences (EXAS) Q3 Earnings Expected to DeclineOctober 26, 2022 | finance.yahoo.comCRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Should You Buy?See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CRSP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CRSP Company Calendar Last Earnings11/03/2021Today2/03/2023Next Earnings (Estimated)2/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CRSP CUSIPN/A CIK1674416 Webwww.crisprtx.com Phone(141) 561-3277FaxN/AEmployees473Year FoundedN/APrice Target and Rating Average Stock Price Forecast$98.22 High Stock Price Forecast$220.00 Low Stock Price Forecast$37.00 Forecasted Upside/Downside+75.4%Consensus RatingModerate Buy Rating Score (0-4)2.53 Research Coverage17 Analysts Profitability EPS (Most Recent Fiscal Year)($8.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$377.66 million Net Margins-4,831.79% Pretax Margin-4,782.84% Return on Equity-31.34% Return on Assets-26.77% Debt Debt-to-Equity RatioN/A Current Ratio12.81 Quick Ratio12.81 Sales & Book Value Annual Sales$914.96 million Price / Sales4.79 Cash Flow$5.73 per share Price / Cash Flow9.77 Book Value$31.35 per share Price / Book1.79Miscellaneous Outstanding Shares78,290,000Free Float74,144,000Market Cap$4.39 billion OptionableOptionable Beta1.66 Key ExecutivesDr. Rodger Novak M.D. (Age 55)Founder, Chairman & Pres Dr. Samarth Kulkarni (Age 43)CEO & Director Comp: $1.18MDr. Lawrence Otto Klein Ph.D. (Age 40)Chief Operating Officer Comp: $675kMr. James R. Kasinger (Age 50)Gen. Counsel & Sec. Comp: $648.93kMr. Shaun FoyFounderDr. Emmanuelle Marie CharpentierCo-Founder & Scientific Advisory Board MemberDr. Craig C. Mello Ph.D.Scientific Founder & Advisory Board MemberDr. Chad Cowan Ph.D.Scientific FounderDr. Matthew Porteus M.D. (Age 56)Ph.D., Scientific Founder & Advisory Board Member Dr. Daniel G. Anderson Ph.D.Scientific Founder & Advisory Board MemberMore ExecutivesKey CompetitorsDenali TherapeuticsNASDAQ:DNLIVir BiotechnologyNASDAQ:VIRGinkgo BioworksNYSE:DNAVaxcyteNASDAQ:PCVXAbcamNASDAQ:ABCMView All CompetitorsInsiders & InstitutionsSimplex Trading LLCBought 47,800 shares on 2/2/2023Ownership: 0.000%SG Americas Securities LLCBought 14,493 shares on 2/2/2023Ownership: 0.035%Profund Advisors LLCBought 227 shares on 2/2/2023Ownership: 0.011%Intellectus Partners LLCSold 364 shares on 2/2/2023Ownership: 0.010%Bay Colony Advisory Group Inc d b a Bay Colony AdvisorsSold 200 shares on 2/1/2023Ownership: 0.009%View All Insider TransactionsView All Institutional Transactions CRSP Stock - Frequently Asked Questions Should I buy or sell CRISPR Therapeutics stock right now? 17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CRISPR Therapeutics in the last year. There are currently 1 sell rating, 6 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CRSP shares. View CRSP analyst ratings or view top-rated stocks. What is CRISPR Therapeutics' stock price forecast for 2023? 17 Wall Street analysts have issued 12-month target prices for CRISPR Therapeutics' shares. Their CRSP share price forecasts range from $37.00 to $220.00. On average, they anticipate the company's stock price to reach $98.22 in the next year. This suggests a possible upside of 75.0% from the stock's current price. View analysts price targets for CRSP or view top-rated stocks among Wall Street analysts. How have CRSP shares performed in 2023? CRISPR Therapeutics' stock was trading at $40.65 on January 1st, 2023. Since then, CRSP shares have increased by 38.1% and is now trading at $56.12. View the best growth stocks for 2023 here. Are investors shorting CRISPR Therapeutics? CRISPR Therapeutics saw a decline in short interest during the month of January. As of January 15th, there was short interest totaling 9,880,000 shares, a decline of 5.7% from the December 31st total of 10,480,000 shares. Based on an average daily trading volume, of 1,080,000 shares, the short-interest ratio is presently 9.1 days. Approximately 13.2% of the company's shares are short sold. View CRISPR Therapeutics' Short Interest. When is CRISPR Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 21st 2023. View our CRSP earnings forecast. How were CRISPR Therapeutics' earnings last quarter? CRISPR Therapeutics AG (NASDAQ:CRSP) released its earnings results on Wednesday, November, 3rd. The company reported ($1.67) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.75) by $0.08. The company earned $0.82 million during the quarter, compared to analyst estimates of $3.85 million. CRISPR Therapeutics had a negative trailing twelve-month return on equity of 31.34% and a negative net margin of 4,831.79%. What other stocks do shareholders of CRISPR Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other CRISPR Therapeutics investors own include NVIDIA (NVDA), Editas Medicine (EDIT), Alibaba Group (BABA), Micron Technology (MU), Advanced Micro Devices (AMD), Block (SQ), Tesla (TSLA), Intellia Therapeutics (NTLA), QUALCOMM (QCOM) and Shopify (SHOP). When did CRISPR Therapeutics IPO? (CRSP) raised $75 million in an initial public offering on Wednesday, October 19th 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays served as the underwriters for the IPO and Guggenheim Securities was co-manager. What is CRISPR Therapeutics' stock symbol? CRISPR Therapeutics trades on the NASDAQ under the ticker symbol "CRSP." Who are CRISPR Therapeutics' major shareholders? CRISPR Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include ARK Investment Management LLC (10.00%), Sumitomo Mitsui Trust Holdings Inc. (5.12%), Baillie Gifford & Co. (0.34%), Allspring Global Investments Holdings LLC (0.33%), Capital Advisors Inc. OK (0.17%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Bradley J Phd Bolzon, Bradley J Phd Bolzon, James R Kasinger, Lawrence Otto Klein, Michael John Tomsicek, Rodger Novak, Samarth Kulkarni, Tony W Ho and Tony W Ho. View institutional ownership trends. How do I buy shares of CRISPR Therapeutics? Shares of CRSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is CRISPR Therapeutics' stock price today? One share of CRSP stock can currently be purchased for approximately $56.12. How much money does CRISPR Therapeutics make? CRISPR Therapeutics (NASDAQ:CRSP) has a market capitalization of $4.39 billion and generates $914.96 million in revenue each year. The company earns $377.66 million in net income (profit) each year or ($8.80) on an earnings per share basis. How many employees does CRISPR Therapeutics have? The company employs 473 workers across the globe. How can I contact CRISPR Therapeutics? CRISPR Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The official website for the company is www.crisprtx.com. The company can be reached via phone at (141) 561-3277 or via email at susan.kim@crisprtx.com. This page (NASDAQ:CRSP) was last updated on 2/3/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.